Venous thromboembolism prophylaxis post-discharge in hip fracture surgery patients: what to do if the patient is taking antiplatelets

Authors: Andrew Porter, Shuli Levy and Michael Fertleman

Aims
To assess whether adequate post-discharge venous thromboembolism (VTE) prophylaxis is prescribed to patients who underwent hip fracture surgery (HFS) and to consider what should be prescribed to patients who are already taking antiplatelet agents.

Methods
A retrospective study analysed discharge prescriptions of HFS patients at a London teaching hospital over a 10-week period. Both anticoagulant and antiplatelet prescriptions were recorded. A re-audit was then carried out again over a 10-week period.

Results
In the initial audit, 40 patients had HFS and had been discharged with a completed discharge prescription. The repeat audit included 41 patients. The results are shown in the table below.

Table 1. VTE prophylaxis post-discharge.

<table>
<thead>
<tr>
<th>Adequate VTE prophylaxis</th>
<th>Inadequate VTE prophylaxis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patients discharged on anticoagulant</td>
<td>Patients discharged on single antiplatelet and anticoagulant</td>
</tr>
<tr>
<td>Initial audit</td>
<td>Re-audit</td>
</tr>
<tr>
<td>12</td>
<td>14a</td>
</tr>
<tr>
<td>30 %</td>
<td>34 %</td>
</tr>
</tbody>
</table>

> Patients taking single antiplatelet therapy should also receive rivaroxaban for 5 weeks.
> Those taking dual antiplatelet therapy should not receive additional thromboprophylaxis owing to increased bleeding risk.
> Those on warfarin require no added prophylaxis.

Using this, 34% of patients in the initial audit and 56% in the re-audit received adequate post-discharge VTE prophylaxis. More should be done to ensure that appropriate prophylaxis is prescribed and guidelines should be updated to include recommendations on prophylaxis in patients taking antiplatelets.

Conflict of interest statement
There was no conflict of interest in this audit.

Analysis of our initial results demonstrated poor compliance with these guidelines, partly owing to inadequate guidance on what to prescribe to those taking single or dual antiplatelet therapy. A literature review found no relevant evidence-based guidelines. We therefore created new guidelines based on the consensus opinion of the trust VTE task force, as follows.

 Authors: Imperial College Healthcare Trust, London, UK